June 2026 Alcon expanded its glaucoma portfolio by introducing next-generation minimally invasive glaucoma surgery (MIGS) technologies designed to improve intraocular pressure management and support earlier surgical intervention for glaucoma patients.
May 2026 AbbVie expanded clinical development activities for innovative glaucoma therapies, advancing research focused on sustained drug delivery systems and novel treatments to improve long-term intraocular pressure control.
April 2026 Santen Pharmaceutical expanded its ophthalmology portfolio through the launch of advanced glaucoma treatment solutions and strengthened collaborations to improve patient access to glaucoma care across international markets.
March 2026 Glaukos expanded its interventional glaucoma portfolio by advancing clinical studies evaluating next-generation micro-invasive glaucoma surgery devices for patients with open-angle glaucoma.